Ensign Peak Advisors
KYNB

Ensign Peak Advisors’s Kyntra Bio KYNB Stock Holding History

Ensign Peak Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-910
Closed -$296K – 1933
2022
Q3 		$296K Buy
910
+142
+18% +$45.7K ﹤0.01% 1710
2022
Q2 		$203K Hold
768
– – ﹤0.01% 1789
2022
Q1 		$231K Hold
768
– – ﹤0.01% 1840
2021
Q4 		$271K Buy
+768
New +$239K ﹤0.01% 1845

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's KYNB Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 910 shares — an estimated $296K sold.

Ensign Peak Advisors first reported a position in KYNB in Q4 2021 and held it in 4 quarters. The position peaked at $296K in Q3 2022. 144 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 910 Kyntra Bio shares in Q4 2022, an estimated $296K.
  • Ensign Peak Advisors first reported a position in Kyntra Bio in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Kyntra Bio position peaked at $296K in Q3 2022.
  • 144 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.